Apart from plasma therapy, COVID-19 patients who are in critical condition, will soon have another kind of treatment, to help fight the infection. Mumbai-based Haffkine Institute, which last month had submitted a proposal to conduct a clinical trial to use the anti-tuberculosis Bacillus Calmette-Guérin (BCG) vaccine, as a therapeutic treatment received a nod for it from the Drug Controller General of India on Friday.

Around 30 COVID-19 patients, who have moderate or severe symptoms, will be part of the trial run, starting next week. "The BCG vaccine strengthens immunity and research has shown that it can be used as a therapeutic treatment, to help patients fight the infection. We received an approval from the DGCI and are waiting for the clinical registration number from the ICMR, which should come in a couple of days," said a senior official from the Medical Education and Drugs (MED) department.